Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.270
+0.010 (0.79%)
At close: Jun 9, 2025, 4:00 PM
1.300
+0.030 (2.36%)
After-hours: Jun 9, 2025, 7:13 PM EDT
Caribou Biosciences Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Caribou Biosciences stock ranges from a low of $3.00 to a high of $14. The average analyst price target of $8.50 forecasts a 569.29% increase in the stock price over the next year.
Price Target: $8.50 (+569.29%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 28, 2025.
Analyst Ratings
The average analyst rating for Caribou Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $3 | Strong Buy | Maintains | $9 → $3 | +136.22% | Apr 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +608.66% | Mar 19, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $13 → $11 | Strong Buy | Maintains | $13 → $11 | +766.14% | Jan 7, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $30 → $6 | Strong Buy | Maintains | $30 → $6 | +372.44% | Nov 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +608.66% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
9.87M
from 9.99M
Decreased by -1.28%
Revenue Next Year
25.83M
from 9.87M
Increased by 161.81%
EPS This Year
-1.39
from -1.65
EPS Next Year
-1.25
from -1.39
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.7M | 105.0M | 105.0M | ||
| Avg | 9.9M | 25.8M | 30.2M | ||
| Low | n/a | 9.7M | 9.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.1% | 964.3% | 306.5% | ||
| Avg | -1.3% | 161.8% | 16.7% | ||
| Low | - | -1.3% | -62.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.86 | -0.53 | 0.03 | ||
| Avg | -1.39 | -1.25 | -1.01 | ||
| Low | -1.85 | -1.68 | -1.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.